Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 12393
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0500nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0630nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0630nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0630nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.135nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.138nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.145nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.174nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.204nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.214nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.224nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.224nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.257nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.288nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.324nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.347nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.347nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.355nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.372nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.372nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.380nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.389nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.389nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.457nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.479nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.603nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.741nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1.05nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1.10nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 4.37nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 4.79nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A isoform 2(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 5.13nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
